Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
April 18, 2024 09:30 ET
|
Grifols, S.A.
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The...
Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus
April 04, 2024 04:00 ET
|
Grifols, S.A.
O teste de ácido nucleico in vitro da Grifols deteta quatro tipos de arbovírus, ajudando a reduzir o risco de infeções transmitidas por transfusãoOs arbovírus são uma ameaça emergente crescente, com...
Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE
April 04, 2024 04:00 ET
|
Grifols, S.A.
Il test NAT in vitro di Grifols rileva quattro tipi di arbovirus, contribuendo a ridurre il rischio di infezioni trasmesse tramite trasfusioneGli arbovirus sono una minaccia emergente in crescita,...
Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren
April 04, 2024 04:00 ET
|
Grifols, S.A.
Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringernArboviren stellen eine wachsende Bedrohung...
Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE
April 04, 2024 04:00 ET
|
Grifols, S.A.
Le test d’acide nucléique in vitro de Grifols détecte quatre types d’arbovirus, contribuant ainsi à la diminution du risque d’infections transmises par transfusion*Les arbovirus constituent une menace...
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
April 04, 2024 04:00 ET
|
Grifols, S.A.
Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in...
Grifols announces positive topline phase 3 fibrinogen clinical trial results
February 14, 2024 03:16 ET
|
Grifols, S.A.
In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard...
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
November 15, 2023 08:00 ET
|
Grifols, S.A.
Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human)...
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
October 24, 2023 18:30 ET
|
Grifols, S.A.
Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease...
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
August 01, 2023 08:00 ET
|
Grifols, S.A.
Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce...